CYP2C9 polymorphism: impact on tolbutamide pharmacokinetics and response

Pharmacogenetics. 2002 Mar;12(2):91-2. doi: 10.1097/00008571-200203000-00002.
No abstract available

Publication types

  • Comment

MeSH terms

  • Alleles
  • Aryl Hydrocarbon Hydroxylases*
  • Blood Glucose / metabolism
  • Cytochrome P-450 CYP2C19
  • Cytochrome P-450 CYP2C9
  • Cytochrome P-450 Enzyme System / genetics*
  • Drug Evaluation
  • Genotype
  • Humans
  • Hypoglycemic Agents / pharmacokinetics*
  • Linkage Disequilibrium
  • Mixed Function Oxygenases / genetics
  • Polymorphism, Genetic / genetics*
  • Population Surveillance
  • Steroid 16-alpha-Hydroxylase*
  • Steroid Hydroxylases / genetics*
  • Tolbutamide / pharmacokinetics*

Substances

  • Blood Glucose
  • Hypoglycemic Agents
  • Cytochrome P-450 Enzyme System
  • Tolbutamide
  • Mixed Function Oxygenases
  • Steroid Hydroxylases
  • CYP2C9 protein, human
  • Cytochrome P-450 CYP2C9
  • Aryl Hydrocarbon Hydroxylases
  • CYP2C19 protein, human
  • Cytochrome P-450 CYP2C19
  • Steroid 16-alpha-Hydroxylase